Abstract:The pharmaceutical industry often depends on statistics to improve product quality, optimize the compositions, streamline operations, and conform to regulatory requirements. In Bio Equivalency investigations, Statistics plays an integral role in decision-making while demonstrating the similarity between the test and reference products. In this review, we explore how statistics play a crucial role in pharmaceutical product development. We start with examining experiments, where statistics help scientists find the best combinations of ingredients and manufacturing conditions. We explored different types of experiments, like factorial designs, Plackett-Burman designs, Box-Behnken designs, and Taguchi designs. While optimizing the formulations and process parameters, these methodologies assist researchers in making meaningful conclusions supported by statistical inference. The next sections include Response Surface Methodology (RSM) and Mixture Designs, which help in the development of drug formulations and the comprehension of complex responses. The development of pharmaceuticals is made simpler by these approaches. Then, we examine optimal designs like A-optimal, I-optimal, and D-optimal. A-optimal designs save resources, I-optimal designs focus on precise estimates, and D-optimal designs are great for screening and getting accurate results. These designs help scientists make decisions based on data. The starting point for demonstrating dissolution similarity between generic and reference products is the statistical approach. This paper examines the use of model-dependent techniques, such as zero-order, first-order, Higuchi, and Weibull models, and model-independent techniques such as F1, F2, Bootstrap, MSD, and PCA techniques, it analyzes important parameters and bounds that are essential for determining the dissolution similarity. In the field of biostatistics, we discuss how statistics ensures that generic drugs are safe and work just as efficiently as brand-name drugs. Both regulatory approval and patient safety rely on this. We briefly discuss statistical process control (SPC) in closing. SPC checks that drugs/drug products are consistently of quality using graphs and figures. It facilitates the production of consistently effective pharmaceuticals by organizations. Advanced statistical techniques, including data mining, machine learning, and artificial intelligence, are revolutionizing the pharmaceutical industry. These tools enhance drug discovery, optimize manufacturing processes, and pave the way for personalized medicine. As real-time monitoring and predictive analytics become integral, the future holds exciting possibilities for improving patient outcomes. This review shows how statistics are like a guiding tool in the pharmaceutical industry. Whether it's in the lab or in manufacturing, statistics play a big role in making sure patients get the best medicines possible.

Development of Quantitative Comparative Approaches to Support Complex Generic Drug Development

Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research Initiatives Public Workshop

Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products

Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model‐Based Bioequivalence

Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report

Generating Model Integrated Evidence for Generic Drug Development and Assessment

Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products—a Meeting Report

Use of the Same Model or Modeling Strategy Across Multiple Submissions: Focus on Complex Drug Products

Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products

Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products

Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development

Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004-2006.

Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs

Innovation for Generic Drugs: Science and Research Under the Generic Drug User Fee Amendments of 2012

Leveraging Numerical Simulation Technology to Advance Drug Preparation: A Comprehensive Review of Application Scenarios and Cases

Statistical Applications in Pharmaceutical Product Development: A Comprehensive Review

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

A Comprehensive Map of FDA-Approved Pharmaceutical Products

The convergence of pharmacometrics and quantitative systems pharmacology in pharmaceutical research and development

Emerging Landscape of Computational Modeling in Pharmaceutical Development